Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Kaposi Sarcoma
100%
Chemotherapy Regimens
60%
Chemotherapy
50%
Disease Exacerbation
50%
Doxorubicin
50%
Daunorubicin
40%
Bleomycin
30%
Disease
20%
Malignant Neoplasm
20%
Observational Study
20%
Adverse Event
20%
Anthracycline
20%
Vincristine
20%
Paclitaxel
20%
Cohort Study
10%
Clinical Trial
10%
Antiretrovirus Agent
10%
Median Survival Time
10%
Randomized Controlled Trial
10%
Etoposide
10%
Immune Reconstitution Inflammatory Syndrome
10%
Vinblastine
10%
Keyphrases
Highly Active Antiretroviral Therapy (HAART)
100%
Kaposi Sarcoma
100%
HIV-infected Adults
100%
Pegylated Liposomal Doxorubicin
39%
Confidence Interval
26%
Risk Ratio
26%
Chemotherapy Regimen
26%
Disease Progression
21%
Chemotherapy
21%
Bleomycin
13%
Common Cancers
8%
Adverse Events
8%
HIV Patients
8%
Group Risk
8%
Randomized Trial
8%
Liposomal Anthracyclines
8%
No Significant Difference
4%
Antiretroviral Therapy
4%
AIDS/HIV
4%
Selection Criteria
4%
Moderate to Severe
4%
Clinical Trial Registry
4%
Median Survival Time
4%
Meta-analysis
4%
MEDLINE
4%
Embase
4%
Sub-Saharan Africa
4%
Overall Mortality
4%
Antiretroviral Naïve
4%
Cochrane Central Register of Controlled Trials
4%
Ongoing Trials
4%
Doxorubicin
4%
Review Authors
4%
Nonrandomized Studies
4%
U.S. National Institutes of Health
4%
Immune Reconstitution
4%
Conference Abstracts
4%
Vinblastine
4%
Mortality Benefit
4%
Effect Measure
4%
Overall Response Rate
4%
Number of Events
4%
Search Methods
4%
Risk of Progression
4%
Oral Etoposide
4%
Non-randomized Trial
4%
Conservative Management
4%
Chemotherapeutic Regimens
4%
Liposomal Paclitaxel
4%
Paclitaxel
4%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Highly Active Antiretroviral Therapy
100%
Kaposi Sarcoma
100%
Chemotherapy Regimens
26%
Disease Exacerbation
21%
Doxorubicin
21%
Chemotherapy
21%
Liposomal Daunorubicin
17%
Bleomycin
13%
Disease
8%
High Risk Population
8%
Malignant Neoplasm
8%
Observational Study
8%
Adverse Event
8%
Anthracycline
8%
Vincristine
8%
Paclitaxel
8%
Clinical Trial
4%
Cohort Analysis
4%
Randomized Controlled Trial
4%
Median Survival Time
4%
Antiretroviral Therapy
4%
HIV/AIDS
4%
Meta-Analysis
4%
Etoposide
4%
Conservative Treatment
4%
Immune Reconstitution Inflammatory Syndrome
4%
Vinblastine
4%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Highly Active Antiretroviral Therapy
100%
Kaposi Sarcoma
100%
Confidence Interval
26%
Disease Exacerbation
21%
Doxil
21%
Daunorubicin
17%
Bleomycin
13%
Malignant Neoplasm
8%
Disease
8%
High Risk Population
8%
Adverse Event
8%
Anthracycline
8%
Vincristine
8%
Paclitaxel
8%
World Health Organization
4%
Antiretroviral Therapy
4%
Cohort Analysis
4%
Meta Analysis
4%
Cochrane Library
4%
National Health Organization
4%
Conservative Treatment
4%
Vinblastine
4%
Chemotherapy
4%
Etoposide
4%
Median Survival Time
4%
Immune Reconstitution Inflammatory Syndrome
4%